论文部分内容阅读
[目的]探讨缬沙坦治疗慢性肾小球肾炎(CG)并高血压患者的合适剂量与疗效.[方法]选取本院肾脏内科收治的96例CG并高血压患者,采取随机数字表法分为高剂量组(320 mg/d缬沙坦口服)和常规剂量组(160mg/d缬沙坦口服),每组各48例,连续用药6个月后评价比较两组患者的临床效果及不良反应.[结果]治疗前两组患者的24 h尿蛋白、血肌酐(SCr)、肾小球滤过率(GFR)、血清K+、尿α1-微球蛋白(α1-MG)、尿N-乙酰-β氨基葡萄糖苷酶(NAG)、半胱氨酸(CysC)的水平两组间比较差异均无显著性(P＜0.05);治疗后,高剂量组患者的24 h尿蛋白、SCr、α1-MG、NAG、CysC的水平显著的低于常规剂量组(P＜0.05),GFR水平显著高于常规剂量组(P＜0.05);高剂量组患者的不良反应发生率为14.58％(7/48)高于常规组的4.17％(2/48),但两组相比较差异无显著性(P＞0.05).[结论]高剂量缬沙坦治疗CG并高血压患者有利于延缓患者肾功能恶化的进程,值得临床推广.“,”[Objective]To study the dose and effect of Valsartan in the treatment of chronic glomerulonephritis (CG) patients with hypertension.[Methods] A total of 96 CG patients complicated with hypertension were selected in the Department of Nephrology in our hospital treated.They were divided according to the random table method into a high-dose group (320 mg/d Valsartan oral) and a conventional-dose group (160mg / d Valsartan oral),with 48 cases in each group.Clinical effects were collected and evaluated after six months of continuous medication.[Results]Before treatment,the levels of 24h urine protein,SCr,GFR,serum K+,α1-MG,NAG,and CysC were not statistically significant difference between the two groups level group (P ＜0.05).After 6-month treatment,the high dose group patients showed lower levels of 24h urine protein,SCr,α1-MG,NAG and CysC and a higher level of GFR compared to the conventional dose group;the differences were statistical significance (P ＜0.05).The incidence of adverse reactions was 14.58％ in the high-dose group and 4.17％ in the conventional dose group,but the difference was not statistically significant (P ＞ 0.05).[Conclusion]High doses of Valsartan treatment in chronic glomerulonephritis patients with hypertension is conducive to delaying the process of deterioration of renal function.It has certain clinical and practical value.